Cooper Companies (NASDAQ:COO) Upgraded at StockNews.com

StockNews.com upgraded shares of Cooper Companies (NASDAQ:COO) from a hold rating to a buy rating in a research report report published on Friday morning.

COO has been the topic of several other research reports. Morgan Stanley raised their price objective on Cooper Companies from $95.00 to $104.00 and gave the company an “equal weight” rating in a report on Tuesday, September 10th. Piper Sandler raised their price target on shares of Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, August 29th. Stifel Nicolaus restated a “buy” rating and issued a $115.00 target price (up previously from $110.00) on shares of Cooper Companies in a report on Thursday, August 29th. Jefferies Financial Group upgraded Cooper Companies from a “hold” rating to a “buy” rating and raised their price objective for the company from $107.00 to $115.00 in a research note on Tuesday, July 16th. Finally, Robert W. Baird upped their price objective on shares of Cooper Companies from $118.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, August 29th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $117.00.

Cooper Companies Stock Down 0.2 %

COO stock opened at $103.55 on Friday. Cooper Companies has a 52 week low of $81.99 and a 52 week high of $112.38. The business has a 50-day simple moving average of $107.26 and a 200 day simple moving average of $97.73. The company has a quick ratio of 1.18, a current ratio of 1.99 and a debt-to-equity ratio of 0.33. The company has a market cap of $20.62 billion, a PE ratio of 57.69, a price-to-earnings-growth ratio of 2.24 and a beta of 0.99.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.91 by $0.05. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $997.30 million. During the same period in the previous year, the company earned $0.84 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. Sell-side analysts anticipate that Cooper Companies will post 3.65 EPS for the current fiscal year.

Insider Transactions at Cooper Companies

In other Cooper Companies news, CEO Albert G. White III sold 114,992 shares of the business’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the sale, the chief executive officer now owns 165,273 shares of the company’s stock, valued at $18,267,624.69. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Cooper Companies news, CEO Albert G. White III sold 114,992 shares of the stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total value of $12,710,065.76. Following the sale, the chief executive officer now directly owns 165,273 shares in the company, valued at $18,267,624.69. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Agostino Ricupati sold 1,601 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total transaction of $172,956.03. Following the completion of the transaction, the chief accounting officer now directly owns 4,818 shares of the company’s stock, valued at approximately $520,488.54. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 256,373 shares of company stock worth $27,637,427. 2.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Cooper Companies

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Cooper Companies by 303.0% in the 1st quarter. Vanguard Group Inc. now owns 23,099,975 shares of the medical device company’s stock worth $2,343,723,000 after buying an additional 17,367,502 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC raised its position in Cooper Companies by 3.0% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 7,820,590 shares of the medical device company’s stock worth $682,738,000 after purchasing an additional 231,155 shares during the period. Capital World Investors lifted its stake in Cooper Companies by 301.7% in the first quarter. Capital World Investors now owns 5,654,023 shares of the medical device company’s stock worth $573,657,000 after purchasing an additional 4,246,519 shares during the last quarter. Victory Capital Management Inc. boosted its position in Cooper Companies by 23.0% during the third quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company’s stock valued at $435,856,000 after buying an additional 737,726 shares during the period. Finally, Janus Henderson Group PLC grew its stake in shares of Cooper Companies by 279.8% during the first quarter. Janus Henderson Group PLC now owns 3,437,064 shares of the medical device company’s stock valued at $348,723,000 after buying an additional 2,532,186 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.